Literature DB >> 3139974

Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

P C Turnbull1, S H Leppla, M G Broster, C P Quinn, J Melling.   

Abstract

A forerunning study on the relationship between antibodies to the protective antigen (PA) and lethal factor (LF) components of anthrax toxin and protective immunity has been expanded and extended to include the third toxin component, the edema factor (EF). It was found that protection against the "vaccine resistant" Ames strain was possible in the absence of detectable anti-LF and anti-EF antibodies. Evidence is given that PA may be the essential anthrax-derived antigen for protection, but that equally essential is that it be presented to the host's immune system in such a manner as to provide stimulation of more than just production of antibody to PA. Titers to the three components in sera of individuals with histories of clinically diagnosed anthrax as well as from human vaccinees are included in the report.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139974     DOI: 10.1007/bf00189414

Source DB:  PubMed          Journal:  Med Microbiol Immunol        ISSN: 0300-8584            Impact factor:   3.402


  6 in total

1.  Immunization studies with attenuated strains of Bacillus anthracis.

Authors:  B E Ivins; J W Ezzell; J Jemski; K W Hedlund; J D Ristroph; S H Leppla
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

2.  Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; M G Broster; J A Carman; R J Manchee; J Melling
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

3.  Purification of anthrax-toxin components by high-performance anion-exchange, gel-filtration and hydrophobic-interaction chromatography.

Authors:  C P Quinn; C C Shone; P C Turnbull; J Melling
Journal:  Biochem J       Date:  1988-06-15       Impact factor: 3.857

4.  Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis.

Authors:  B E Ivins; S L Welkos
Journal:  Infect Immun       Date:  1986-11       Impact factor: 3.441

5.  Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells.

Authors:  S H Leppla
Journal:  Adv Cyclic Nucleotide Protein Phosphorylation Res       Date:  1984

6.  Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.

Authors:  S H Leppla
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

  6 in total
  35 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Phase 1 study of a recombinant mutant protective antigen of Bacillus anthracis.

Authors:  Joseph A Bellanti; Feng-Ying C Lin; Chiayung Chu; Joseph Shiloach; Stephen H Leppla; German A Benavides; Arthur Karpas; Mahtab Moayeri; Chunyan Guo; John B Robbins; Rachel Schneerson
Journal:  Clin Vaccine Immunol       Date:  2011-12-21

Review 3.  Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines.

Authors:  Andrew J Phipps; Christopher Premanandan; Roy E Barnewall; Michael D Lairmore
Journal:  Microbiol Mol Biol Rev       Date:  2004-12       Impact factor: 11.056

4.  Serology and anthrax in humans, livestock and Etosha National Park wildlife.

Authors:  P C Turnbull; M Doganay; P M Lindeque; B Aygen; J McLaughlin
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

5.  Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.

Authors:  Qin Li; Kristina K Peachman; Laurie Sower; Stephen H Leppla; Sathish B Shivachandra; Gary R Matyas; Johnny W Peterson; Carl R Alving; Mangala Rao; Venigalla B Rao
Journal:  Open Vaccine J       Date:  2009

6.  Determination of serum IgG antibodies to Bacillus anthracis protective antigen in environmental sampling workers using a fluorescent covalent microsphere immunoassay.

Authors:  R E Biagini; D L Sammons; J P Smith; E H Page; J E Snawder; C A F Striley; B A MacKenzie
Journal:  Occup Environ Med       Date:  2004-08       Impact factor: 4.402

7.  Serum IgG antibody response to the protective antigen (PA) of Bacillus anthracis induced by anthrax vaccine adsorbed (AVA) among U.S. military personnel.

Authors:  Darrell E Singer; Rachel Schneerson; Christian T Bautista; Mark V Rubertone; John B Robbins; David N Taylor
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

8.  Sequential B-cell epitopes of Bacillus anthracis lethal factor bind lethal toxin-neutralizing antibodies.

Authors:  Melissa L Nguyen; Sherry R Crowe; Sridevi Kurella; Simon Teryzan; Brian Cao; Jimmy D Ballard; Judith A James; A Darise Farris
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

9.  Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals.

Authors:  L C Iacono-Connors; S L Welkos; B E Ivins; J M Dalrymple
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

10.  Specific, sensitive, and quantitative enzyme-linked immunosorbent assay for human immunoglobulin G antibodies to anthrax toxin protective antigen.

Authors:  Conrad P Quinn; Vera A Semenova; Cheryl M Elie; Sandra Romero-Steiner; Carolyn Greene; Han Li; Karen Stamey; Evelene Steward-Clark; Daniel S Schmidt; Elizabeth Mothershed; Janet Pruckler; Stephanie Schwartz; Robert F Benson; Leta O Helsel; Patricia F Holder; Scott E Johnson; Molly Kellum; Trudy Messmer; W Lanier Thacker; Lilah Besser; Brian D Plikaytis; Thomas H Taylor; Alison E Freeman; Kelly J Wallace; Peter Dull; Jim Sejvar; Erica Bruce; Rosa Moreno; Anne Schuchat; Jairam R Lingappa; Sandra K Martin; John Walls; Melinda Bronsdon; George M Carlone; Mary Bajani-Ari; David A Ashford; David S Stephens; Bradley A Perkins
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.